Avian flu fears increase Tamiflu demand

Share this article:

As governments stockpile Roche's Tamiflu to prevent a possible avian flu pandemic, consumer demand is rising too, USA Today reports.
Market researcher Verispan says U.S. prescriptions for Tamiflu hit 34,388 for the week ending Oct. 7, up 713 percent from the same period last year.
Drugstore.com, told the newspaper that it has sold more Tamiflu in the past five weeks than in the last six months of last year. "Demand is off the charts," a spokesman for the company said.
The U.S. has stockpiled enough anti-virals to treat 1 percent of the population and recently announced plans to get enough to treat 20 million people. Switzerland-based Roche, which doubled manufacturing capacity in 2004, will double it again this year, launch some manufacturing in the U.S. and add more capacity next year, the firm said.
Meanwhile, GlaxoSmithKline said it is making more of its anti-viral treatment Relenza. The U.S. government is buying 84,300 treatments.
Through the first half of 2005, Tamiflu sales hit $450 million, Roche said, compared with $255 million for all of 2004. Relenza sales in 2004 were $5.5 million.

 

Share this article:

Email Newsletters

More in News

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.